Sign up to save your podcasts
Or
Share 298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver disease.
View all episodes
By STAT
4.6
300300 ratings
Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver disease.
More shows like The Readout Loud
View all
WSJ Tech News Briefing
1,636 Listeners
WSJ What’s News
4,302 Listeners
The Daily
111,723 Listeners
KFF Health News' 'What the Health?'
469 Listeners
The Long Run with Luke Timmerman
117 Listeners
The Journal.
5,903 Listeners
Morning Brew Daily
2,927 Listeners
Tradeoffs
383 Listeners
Biotech 2050 Podcast
60 Listeners
Business Of Biotech
84 Listeners
BioCentury This Week
31 Listeners
Raising Health
141 Listeners
Biotech Hangout
9 Listeners
ACQ2 by Acquired
193 Listeners
Ground Truths
44 Listeners